SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Azzi, A. Articles by Castaman, G. Search for Related Content PubMed PubMed Citation Articles by Azzi, A. Articles by Castaman, G. Related Collections Hemostasis, Thrombosis, and Vascular Biology Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 October 2001, Vol. 98, No. 8, pp. 2571-2573 BRIEF REPORT TT virus contaminates first-generation recombinant factor VIII concentrates Alberta Azzi, Riccardo De Santis, Massimo Morfini, Krystyna Zakrzewska, Roberto Musso, Elena Santagostino, and Giancarlo Castaman From the Public Health Department, Microbiology and Virology Unit, University of Florence, Italy; the Hematology Department and Hemophilia Center, Azienda Ospedaliera Careggi, Florence, Italy; the Hematology Department and Hemophilia Center of Catania, Italy; the A. Bianchi Bonomi Hemophilia Center, IRCCS Maggiore Hospital and University of Milan, Italy; and the Hematology Department and Hemophilia Center, San Bortolo Hospital, Vicenza, Italy. Recombinant factor VIII and factor IX concentrates, human-plasma-derived albumin, and samples from previously untreated patients with hemophilia were examined for the presence of TT virus (TTV) by using polymerase chain reaction testing. Blood samples from the patients were obtained prospectively before and every 3 to 6 months after therapy was begun. TTV was detected in 23.5% of the recombinant-product lots and 55.5% of the albumin lots tested. Only first-generation factor VIII recombinant concentrates stabilized with human albumin were positive for TTV, whereas all second-generation (human protein-free) concentrates were negative for the virus. In 59% of patients treated with either first- or second-generation recombinant factor concentrates, TTV infection developed at some point after the initial infusion. Infection with TTV in these patients before and after treatment did not appear to be clinically important. Thus, first-generation recombinant factor VIII concentrates may contain TTV and the source of the viral contamination may be human albumin. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Kekarainen, L. Martinez-Guino, and J. Segales Swine torque teno virus detection in pig commercial vaccines, enzymes for laboratory use and human drugs containing components of porcine origin J. Gen. Virol., March 1, 2009; 90(3): 648 - 653. [Abstract] [Full Text] [PDF] T. R. Kreil, K. Zimmermann, S. Pable, H. P. Schwarz, F. Dorner, A. Azzi, and M. Morfini TT virus does not contaminate first-generation recombinant factor VIII concentrate Blood, August 28, 2002; 100(6): 2271 - 2271. [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020